Login | Register

Vorapaxar Reduced Cardiovascular Events But Increased Bleeding In Large Trial

Adding Vorapaxar to standard treatment for patients with a medical history of cardiovascular events or disease was found to reduce cardiovascular events, but also increased bleeding significantly, including intracranial hemorrhage. The researchers added that ICH (intracranial hemorrhage) risk was lower for those with no history of stroke...

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *